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Abstract
 Background—Diabetes is a highly prevalent and costly disease. Studies indicate that 
combined diet and physical activity promotion programs can prevent type 2 diabetes among 
persons at increased risk.
 Purpose—To systematically evaluate the evidence on cost, cost-effectiveness, and cost-benefit 
estimates of diet and physical activity promotion programs.
 Data Sources—Cochrane Library, EMBASE, MEDLINE, PsycINFO, Sociological Abstracts, 
Web of Science, EconLit, and CINAHL through 7 April 2015.
 Study Selection—English-language studies from high-income countries that provided data 
on cost, cost-effectiveness, or cost-benefit ratios of diet and physical activity promotion programs 
with at least 2 sessions over at least 3 months delivered to persons at increased risk for type 2 
diabetes.
 Data Extraction—Dual abstraction and assessment of relevant study details.
 Data Synthesis—Twenty-eight studies were included. Costs were expressed in 2013 U.S. 
dollars. The median program cost per participant was $653. Costs were lower for group-based 
programs (median, $417) and programs implemented in community or primary care settings 
(median, $424) than for the U.S. DPP (Diabetes Prevention Program) trial and the DPP Outcomes 
Study ($5881). Twenty-two studies assessed the incremental cost-effectiveness ratios (ICERs) of 
the programs. From a health system perspective, 16 studies reported a median ICER of $13 761 
per quality-adjusted life-year (QALY) saved. Group-based programs were more cost-effective 
(median, $1819 per QALY) than those that used individual sessions (median, $15 846 per QALY). 
No cost-benefit studies were identified.
 Limitation—Information on recruitment costs and cost-effectiveness of translational programs 
implemented in community and primary care settings was limited.
 Conclusion—Diet and physical activity promotion programs to prevent type 2 diabetes are 
cost-effective among persons at increased risk. Costs are lower when programs are delivered to 
groups in community or primary care settings.
 Primary Funding Source—None.
Diabetes is a highly prevalent, severe, and costly disease in the United States. 
Approximately 29 million Americans (9.3% of the U.S. population) had diabetes in 2012, 
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and that number is projected to increase (1, 2). Diabetes is the leading cause of kidney 
failure, blindness, and amputation, as well as a major cause of heart disease and stroke (2). 
In the United States in 2012, the total medical cost of diagnosed diabetes was estimated at 
$176 billion, and the cost of productivity loss due to diabetes was another $69 billion (3).
Type 2 diabetes accounts for 90% to 95% of all cases of diagnosed diabetes. Common risk 
factors for type 2 diabetes include obesity, family history of diabetes, physical inactivity, 
hypertension, hypercholesterolemia, and elevated glucose level. In addition, approximately 
37% of the U.S. population aged 20 years or older and 51% of those aged 65 years or older 
had prediabetes in 2012, meaning that they were at increased risk for type 2 diabetes (2). 
However, only about 10% of at-risk persons knew their risk status (4).
Randomized clinical trials around the world have shown that combined diet and physical 
activity promotion programs could prevent or delay progression to type 2 diabetes among 
persons at increased risk (5–8). Studies have also demonstrated the feasibility and 
effectiveness of such programs when they are implemented in primary care or community 
settings (9). In 2014, a systematic review done for the Community Preventive Services Task 
Force found that programs implemented in health care or community settings effectively 
reduced the risk for diabetes in persons at increased risk; increased the likelihood of 
reversion to normoglycemia; and reduced weight and other risk factors for cardiovascular 
disease, such as elevated blood pressure and lipid levels (10).
Given the potentially large population that is eligible for diet and physical activity promotion 
programs and the resources needed for implementation, information on program cost and 
cost-effectiveness is critical for policy decisions, such as benefit coverage for payers, as well 
as planning for program design and implementation. As a companion to the aforementioned 
effectiveness review, we did this systematic economic review for the Community Preventive 
Services Task Force to estimate the cost associated with diet and physical activity promotion 
programs and the cost-effectiveness and cost-benefit ratios of these programs.
 Methods
 Data Sources and Searches
We searched the Cochrane Library, EMBASE, MEDLINE, PsycINFO, Sociological 
Abstracts, Web of Science, EconLit, and CINAHL for English-language articles published 
between January 1985 and 7 April 2015. Details of the search strategy are available on the 
Guide to Community Preventive Services (Community Guide) Web site 
(www.thecommunityguide.org) and in Appendix Table 1 (available at www.annals.org) (11). 
We also screened reference lists of relevant studies and reviews and considered studies 
identified by the parallel review of the effectiveness of diet and physical activity promotion 
programs (10).
 Study Selection
We included studies that provided information on program cost; cost-benefit ratio; or 
incremental cost-effectiveness ratio (ICER), which is measured as dollars per life-year 
gained (LYG), quality-adjusted life-year (QALY) saved, or disability-adjusted life-year 
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(DALY) averted. Included studies on program cost had to evaluate the actual program 
implementation cost. Included cost-effectiveness or cost–benefit studies had to meet 
published criteria for conducting and reporting economic evaluation analysis (12).
We used the same inclusion criteria as the aforementioned effectiveness review for study 
population, intervention, comparison population, and publication language (10). Criteria 
included a population at increased risk for type 2 diabetes, based on glycemic measures or 
risk scores for diabetes, presence of cardiovascular disease, or presence of the metabolic 
syndrome; intervention with both diet and physical activity components delivered in at least 
2 contact sessions over at least 3 months; comparison with a similar population receiving 
either usual care (standard lifestyle advice) or no intervention for the cost-effectiveness 
studies; and publication in English. We further restricted our review to studies in high-
income countries to provide economic estimates relevant to U.S. settings and populations.
 Data Extraction and Quality Assessment
Two authors extracted data from each article according to the Cochrane systematic review 
protocol (13) and the Community Guide protocol for economic evaluations (14).
 Data Synthesis and Analysis
Intervention costs are reported as program costs per participant, including costs to identify 
eligible participants (through recruitment in the community, referral from providers, or 
screening and referral in study settings) and to implement the diet and physical activity 
promotion program (staff time, training materials, and other costs). We also generated 
program costs per participant per session, calculated by dividing program costs per 
participant by the total number of core and maintenance sessions delivered. Medians and 
interquartile intervals (IQIs) of study estimates were reported as summary measures. If there 
were 4 data points, we reported the range; if there were 3 or fewer data points, all were 
reported.
Subgroup analyses of intervention costs were done to explore potential factors affecting 
costs. For delivery setting, we grouped each study into those based on the U.S. DPP 
(Diabetes Prevention Program) study, in which the intervention was delivered in a clinical 
trial setting following rigorous procedures as described in study protocols (5), and those 
done in real-world settings, in which diet and physical activity promotion programs were 
translated to community or primary care settings, with (translational DPP programs) or 
without (translational non-DPP programs) explicit adaptation of DPP training materials.
For delivery method, we categorized each study into 1 of the following groups: individual-
based programs, in which a participant met 1-on-1 with the program provider at each core 
session; group-based programs, in which the participants met as a group with the program 
provider at each core session; or mixed programs, in which the core sessions included both 
individual and group sessions.
For the type of personnel delivering the program, we grouped each study by whether the 
program was delivered by health professionals (such as medical staff, physicians, nurses, 
physiotherapists, case managers, or dietitians), trained laypersons (such as certified diabetes 
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educators, lay health educators, trained community health workers, or trained volunteers 
with type 2 diabetes), or a mix of health professionals and trained laypersons.
Cost-effectiveness estimates were measured as ICERs, with medians and IQIs provided as 
summary measures. To improve comparability of ICERs across the studies, we reported 
them separately by the outcome measures used in different studies: QALYs saved, LYGs, or 
DALYs averted. For studies found to be cost-saving, we calculated the negative net cost per 
QALY saved, LYG, or DALY averted whenever possible to calculate the median ICER.
Two economic perspectives were considered: the health system perspective, in which only 
medical costs and benefits relevant to health systems were considered, and the societal 
perspective, in which direct non-medical and indirect costs were also considered. When 
studies provided sufficient data, we calculated ICERs for perspectives beyond those 
reported.
As with cost estimates, subgroup analysis of ICERs was done by delivery method. We 
examined cost-effectiveness estimates by type of analysis: within-trial analysis, in which 
ICERs were calculated from data on actual costs and benefits; modeling of a trial or 
extension of trials, in which studies used simulation models to estimate program cost and 
effectiveness during or beyond the trial period; or modeling of the national effect, in which 
studies estimated ICERs for programs delivered by scaling up programs to the entire country 
in which the study was conducted.
Because time horizon is important in program planning and budget allocation, we reported 
ICERs by length of follow-up (short-term [<10 years] or long-term [≥10 years]). In addition, 
we reported ICERs stratified by country setting (U.S.- or non–U.S.-based) to better inform 
programs in the United States.
All costs were adjusted to 2013 U.S. dollars by using the Consumer Price Index for medical 
care services (15) and annual foreign exchange rates from the Federal Reserve Bank for 
conversion of other currencies (16). If a study did not mention the year used in cost 
calculations, we assumed costs to be as of 1 year before the study publication year. 
Interventions were considered cost-effective if the ICER was less than $50 000 per QALY 
saved, less than $50 000 per LYG (17), or less than the per capita gross domestic product of 
the relevant country for cost per DALY averted, as recommended by the World Health 
Organization (18).
 Role of the Funding Source
This study was done by employees of the U.S. government as part of their official duties and 
received no external funding.
 Results
After screening, 28 studies met our inclusion criteria and were included in our final review 
(Figure 1) (19–46). Of these, 6 cost-only studies (20–23, 26, 27) and 6 cost-effectiveness 
studies (19, 24, 25, 28–30) provided information on the actual cost of diet and physical 
activity promotion programs, and 22 contributed cost-effectiveness estimates of the 
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programs (19, 24, 25, 28–46). Fourteen studies were U.S.-based (19–24, 26, 27, 31, 35–38, 
46). No cost–benefit studies were identified.
 Intervention Costs
Of the 12 studies that reported the actual costs of implementing the program (20–31), only 4 
included costs for identifying persons at increased risk (22, 24, 27, 29). The major cost 
driver was staff time to deliver the intervention. Most studies provided program cost 
information embedded in an evaluation of program effectiveness or cost-effectiveness 
without doing a formal cost analysis (Appendix Table 2, available at www.annals.org).
Program costs per participant ranged from $191 to $5881 (median, $653 [IQI, $383 to 
$1160]). The most expensive program was the 10-year DPP/DPPOS (Diabetes Prevention 
Program Outcomes Study), which cost $5881 per participant (19). The cost from the first 3 
years (the trial period for DPP, which was based on individual sessions delivered by health 
professionals) was $4687; the remaining maintenance and follow-up period, called the 
DPPOS period, was group-based and accounted for only $1194. The translational programs 
were less intense than the DPP trial and usually had fewer sessions and shorter duration. 
Most of them were group-based or had a mixture of group and individual sessions and were 
delivered by either trained laypersons or a mix of health professionals and trained laypersons 
(Appendix Table 2). They were also less costly than the DPP trial. The median program cost 
per participant was $424 (IQI, $340 to $793) for the 8 translational DPP programs (20–27) 
and $1160 (range, $427 to $1416; 4 data points) for the 3 translational non-DPP programs 
(28–30) (Table 1).
The median cost per participant per session was $30. The cost per session of the DPP/
DPPOS was $102. The median costs per participant per session for the 8 translational DPP 
programs and the 3 translational non-DPP programs were $25 (IQI, $16 to $48) and $27 
(range, $4 to $64), respectively (Table 1).
The median cost per participant was lower in the group-based programs ($417 [IQI, $341 to 
$600]) (20– 25, 28, 29) than in the DPP/DPPOS ($5881) (19) and the translational non-DPP 
program ($1242) (29) (Appendix Table 2), both of which used individual sessions. It was 
also lower than the median cost of programs with a mix of individual and group sessions 
(median, $918 [range, $839 to $1416]) (26, 27, 30) (Table 1). The median cost per 
participant for translational programs delivered by trained laypersons (median, $357 [range, 
$191 to $839]) (21, 22, 26) was lower than that for those delivered by health professionals 
(median, $1077 [IQI, $381 to $1329]; 4 programs; 5 data points) (20, 28–30); however, there 
was large variation within personnel type, possibly due to a mixture of delivery settings and 
methods (Table 1).
 Cost-Effectiveness of the Programs
Of 22 studies reporting the cost-effectiveness of the programs, 8 were U.S.-based (19, 24, 
31, 35–38, 46). Seventeen studies reported the outcome measure as cost per QALY saved 
(19, 24, 25, 28–31, 35–40, 42– 44, 46), 6 reported cost per LYG (32–34, 39, 40, 43), and 2 
reported cost per DALY averted (41, 45). All studies except 1 (42) reported ICERs from a 
health system perspective. Eight studies (19, 28, 31, 36, 38, 39, 42, 44) reported ICERs from 
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a societal perspective, and 7 (19, 28, 31, 36, 38, 39, 44) reported both health system and 
societal perspectives. However, only 1 study included all of the costs and benefits from 
society as a whole (44). Eighteen studies used modeling techniques (24, 28, 30, 32–46), 2 of 
which modeled the cost-effectiveness of nationwide community-based programs (45, 46). 
Fourteen studies were based on data from the DPP trial or the Finnish Diabetes Prevention 
Study, which used individual sessions (19, 31, 33–41, 43, 44, 46). Most modeling studies 
considered the health and cost consequences of the program for at least 10 years (28, 30, 32–
43, 45, 46). Appendix Table 3 (available at www.annals.org) provides estimates of cost-
effectiveness or cost–utility ratios from individual studies, which served as the basis for the 
summary measure of ICERs.
Of the 16 studies that included cost per QALY saved from the health system perspective, all 
but 1 (35) reported ICERs below the cost-effectiveness threshold of $50 000 per QALY 
saved (Figure 2). Three studies reported cost savings (36, 43, 46). The median ICER from 
the 16 studies was $13 761 per QALY saved (IQI, $3067 to $21 899).
From the health system perspective, subgroup analyses were done with 5 studies that 
reported ICERs for both individual- and group-based programs (19, 31, 35, 36, 38). The 
medians were $15 846 (IQI, $7980 to $72 723) and $1819 (IQI, −$5027 to $16 443) per 
QALY, respectively. Six studies (24, 25, 28–30, 46) that evaluated the cost-effectiveness of 
translational programs found a median ICER of $7115 per QALY (IQI, $2252 to $27 582). 
Two of them were conducted in the United States (24, 46); 1 reported an ICER of $5494 per 
QALY, and the other reported cost savings.
Studies in the United States reported a median ICER of $9824 per QALY (IQI, $1930 to $41 
982; 8 studies), and non-U.S. studies reported a median ICER of $13 860 per QALY (IQI, 
$6203 to $21 899; 8 studies). By method, the median ICER of the 4 within-trial analyses 
was $28 097 per QALY (range, $5359 to $50 694) (19, 25, 29, 31). Twelve modeling studies 
reported a median ICER of $13 367 per QALY (IQI, $2303 to $17 614). By time horizon, 
the median ICERs were $17 614 per QALY (IQI, $5427 to $45 521; 5 studies) for studies 
that considered the benefits and costs of the program over less than 10 years and $13 367 per 
QALY (IQI, $1805 to $15 846; 11 studies) for studies that extended 10 years or beyond 
(Table 2).
Two studies conducted in Australia (41, 45) reported cost per DALY averted from the health 
system perspective and used the Australian 2013 per capita gross domestic product of $67 
468 as the cost-effectiveness threshold (47). Both studies found the programs to be cost-
effective ($21 195 and $50 707 per DALY).
Six other studies reported ICERs as cost per LYG (32–34, 39, 40, 43); all were below the 
$50 000 threshold. Two studies showed negative costs per LYG, which indicated cost 
savings (34, 43). The median ICER was $2684 per LYG (IQI, −$2444 to $17 410).
 Discussion
Our review found a median ICER for diet and physical activity promotion programs of $13 
761 per QALY saved. The 25th and 75th percentiles of the ICERs from the 16 studies that 
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reported cost per QALY saved from the health system perspective were both under $50 000 
per QALY, which is a conventional cost-effectiveness threshold (17). The ICERs of diet and 
physical activity promotion programs measured by cost per LYG or DALY averted were also 
all under commonly used cost-effectiveness thresholds (18). Thus, we conclude that diet and 
physical activity promotion programs are cost-effective and involve an efficient use of health 
care resources.
Our evidence search identified 4 pertinent systematic or narrative reviews evaluating the 
evidence on cost-effectiveness of diet and physical activity promotion programs for 
participants at increased risk for type 2 diabetes (48–51). Results from these reviews also 
suggested that such programs were either cost-effective or cost-saving, independent of 
country or delivery setting. Previous reviews did not synthesize evidence on costs of diet and 
physical activity promotion programs. Our systematic review includes 18 additional studies; 
supports the overall finding of cost-effectiveness; and provides comparative economic 
estimates by delivery method, setting, and staffing to inform program planning and 
implementation.
Given the current evidence base, we cannot definitively conclude that the programs are cost-
saving. Only 3 studies that reported cost per QALY saved found the program to be cost-
saving (36, 43, 46). For the 2 U.S. studies, 1 (36) reported that the DPP program was cost-
saving over a lifetime horizon when delivered in group sessions, and the other (46) reported 
that a nationwide diabetes prevention program became cost-saving in its 11th year, implying 
that the programs may not save costs in the short term. However, few health care 
interventions have been found to be cost-saving, and many medical services that are 
typically covered by insurance have much higher ICERs than the diet and physical activity 
promotion programs (52). In a 2010 review of the cost-effectiveness of interventions for 
diabetes prevention and control, the median ICER for lifestyle interventions was at the low 
end of the spectrum, and the interventions were much more cost-effective than many 
diabetes treatment interventions, such as intensive glycemic control (48).
Most cost-effectiveness studies in our review were model-based because most trials lasted 3 
years or less, but both the health and economic effects of the program were expected to last 
beyond the trial period. Estimated long-term ICERs of the programs from those modeling 
studies provided valuable information for decision makers in forecasting the health and 
economic effects of the program. One common critique of model-based studies is a lack of 
transparency of the models. To ensure the validity of the estimates, we explicitly abstracted 
studies in which information on program cost and effectiveness was clearly described in the 
model. Most studies used either a previously validated model or a model used in previous 
peer-reviewed publications, and all studies explicitly stated important assumptions used to 
predict future health and economic outcomes of the program. Model-based ICER estimates 
varied widely, which could have been due to different model structures and health 
assumptions, such as the rates of progression of diabetes and its complications beyond the 
trial period. Despite this variation in the derivation of ICERs with the use of modeling, all 
but 1 study showed that the ICERs of the programs were far below conventional cost-
effectiveness thresholds. The 1 study that reported a much higher ICER used a model with a 
structure that differed greatly from the other studies and assumed a much slower rate of 
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progression to diabetes in the model (35). However, even for this study, when the 
intervention was delivered in a group setting, the ICER was below the threshold of $50 000 
per QALY.
Our findings have several important implications for programs implemented in the field, 
such as the National Diabetes Prevention Program, a public–private partnership led by the 
Centers for Disease Control and Prevention to implement a low-cost intervention adapted 
from the DPP in communities across the country (53). Group-based programs were less 
costly and more cost-effective than individual-based programs. In group-based programs, 
several participants could be counseled in the same session; thus, the cost per participant was 
lower. Evidence also showed that group-based programs may achieve effectiveness similar 
to that for individual-based programs (10). To reduce cost and achieve higher cost-
effectiveness of diet and physical activity promotion programs, it seems that group-based 
programs should be used when the programs are implemented in real-world settings.
The cost of these programs may present a barrier to implementation despite the evidence on 
program cost-effectiveness. The original DPP trial was individual-based and resource-
intensive. However, the program cost was much lower when it was implemented in a group 
format in primary care clinics and communities or translational DPP programs and was 
lower than or similar to currently reimbursable medical practices. For example, the annual 
per capita expenditure (in 2012 U.S. dollars) on prescription medications for persons with 
diabetes was $1423 (3), and Medicare currently pays $25.52 per counseling session for 
weight-loss programs (54). Further, program scale-up is expected to create economies of 
scale, further reducing the cost. Programs were found to be more cost-effective in longer-
term follow-up studies, given that health benefits often last beyond the program period. In 
addition, many diabetes-related complications do not appear immediately after a person 
develops diabetes, which limits the ability of short-term studies to capture the full range of 
health benefits and medical costs avoided by the intervention.
We identified several limitations of the evidence base that future research should address. 
First, few studies estimated the cost associated with recruiting and engaging eligible persons 
to participate in the programs, which may generate additional costs when the programs are 
scaled up. Second, only 2 studies provided a rigorous cost analysis, and there is a lack of 
information to better understand the cost of scaling up the programs, such as the cost of 
programs delivered by trained laypersons (27). Third, only 2 studies evaluated the cost-
effectiveness of programs implemented in primary care and community settings in the 
United States. Fourth, although the societal perspective is often preferred, of the 22 cost-
effectiveness studies identified, only 8 reported this perspective and only 1 included all cost 
and benefit components (12). In addition, 1 study reported an ICER from a health plan 
(payer) perspective. Fifth, no cost-benefit analyses were identified in the review. Finally, 
although we attempted to stratify ICERs by program features, these characteristics were so 
intertwined that formal statistical testing of the effect of a single feature was not feasible.
In summary, the available economic evidence indicates that combined diet and physical 
activity promotion programs are cost-effective when delivered to persons at increased risk 
for type 2 diabetes. Evidence further suggests that programs using group sessions delivered 
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by trained diabetes educators or laypersons are an economically efficient approach for 
communities and health care systems, especially those faced with limited resources and an 
increasing demand for services.
Health care providers have an essential role in the prevention of type 2 diabetes among 
patients at increased risk. In most cases, clinicians will be involved in identifying at-risk 
patients, delivering initial or ongoing behavioral counseling (55), and arranging referrals to 
available services. Our findings, combined with the findings from the concurrent 
effectiveness review (10), add to the growing body of evidence that diet and physical activity 
promotion programs using group sessions delivered by trained personnel are both effective 
and cost-effective. As national, state, and local efforts to implement evidence-based 
programs expand, health care providers will have additional, effective intervention options 
for patients identified as being at increased risk for type 2 diabetes.
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 Appendix
Appendix Table 1
Search Strategy: Combined Diet and Physical Activity Promotion Programs Among Persons 
at Increased Risk—Economic Review*
Number Searches
Terms defining diabetes
 1 exp diabetes mellitus/
 2 diabet$.tw.
 3 IDDM.tw.
 4 NIDDM.tw.
 5 MODY.tw.
 6 (late onset adj diabet$).tw.
 7 (maturity onset adj diabet$).tw.
 8 (juvenil adj diabet$).tw.
 9 (syndrome X and diabet$).tw.
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Number Searches
 10 hyperinsulin$.tw.
 11 insulin sensitiv$.tw.
 12 insulin$ secret$ dysfunc$.tw.
 13 impaired glucose toleran$.tw.
 14 exp glucose intolerance/
 15 glucose intoleran$.tw.
 16 exp insulin resistance/
 17 insulin$ resist$.tw.
 18 (non insulin$ depend$ or noninsulin$ depend$ or non insulin?depend$ 
or noninsulin?depend$).tw.
 19 (insulin$ depend$ or insulin?depend$).tw.
 20 metabolic$ syndrom$.tw.
 21 (pluri metabolic$ syndrom$ or plurimetabolic$ syndrom$).tw.
 22 ((typ$ 1 or typ$ 2) and diabet$).tw.
 23 ((typ I or typ$ II) and diabet$).tw.
 24 or/1–23
 25 exp diabetes insipidus/
 26 diabet$ insipidus.tw.
 27 25 or 26
 28 24 not 27
Terms defining cost
 29 exp “costs and cost analysis”/
 30 exp health care costs/
 31 exp “cost of illness”/
 32 * ECONOMICS/
 33 or/29–32
Terms defining benefit
 34 benefit.mp.
 35 (cost$ or expenditure$).mp.
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Number Searches
 36 Life years.mp.
 37 exp Quality-Adjusted Life Years/
 38 Disability adjusted life years.mp.
 39 effectiveness.mp.
 40 or/34–39
Terms defining both cost and benefit
 41 33 and 40
Additional terms defining cost-
effectiveness analysis or cost–benefit 
analysis
 42 exp COST-BENEFIT ANALYSIS/
 43 cost-effectiveness analysis.mp.
 44 Cost-utility analysis.mp.
 45 Economic evaluation.mp.
 46 or/42–45
 47 28 and (41 or 46)
Terms defining lifestyle interventions 
preventing diabetes
 48 primary prevention/
 49 primary prevention.tw.
 50 (reduc* adj3 risk).tw.
 51 risk reduction behavior/
 52 (prevent* adj3 diabet*).tw.
 53 health promotion.mp.
 54 diabetes mellitus/pc
 55 life style/
 56 lifestyle*.tw.
 57 life style*.tw.
 58 prediabet*.mp.
 59 weight loss/
 60 health education/
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Number Searches
 61 health educator*.mp.
 62 patient education as topic/
 63 diet/
 64 exp exercise/
 65 motor activity/
 66 physical activity.tw.
 67 walking.mp.
 68 or/48–67
 69 47 and 68
Defining searching period
 70
Deduplication of study results limit 69 to yr=“1985-Current”
 71 remove duplicates from 70
*
Databases searched were Cochrane, EMBASE, MEDLINE, PsycINFO, Sociological Abstracts, Web of Science, EconLit, 
and CINAHL. Searches were done between January 1985 and 7 April 2015. Last run: 7 April 2015.
Appendix Table 2
Summary Evidence Table of Included Studies Providing Cost of Combined Diet and 
Physical Activity Promotion Programs to Reduce Type 2 Diabetes Among Persons at 
Increased Risk
Study, Year 
(Reference); Location Population Size, n Population Characteristics Intervention Setting/Intervention Format Duration
Intervention 
Intensity 
(Number of 
Sessions)
Method Type of Personnel
Cost Valuation for 
Identifying Clients 
(Recruitment; 
Screening)
Cost 
Valuation for 
Implementing 
the 
Intervention
Total 
Program 
Costs per 
Person
Cost per 
Person 
per 
Session
DPP/DPPOS
DPP Research Group, 
2012 (19); United States
3,243 Participants with IGT and 
fasting hyperglycemia, aged 
≥25y, BMI ≥24 kg/m2, 
68% women, 45% minority
Clinical trial
Intensive lifestyle modification
10 y Year 1–3: 
Same as DPP
Year 4–10: 4 
quarterly 
group visits, 
with the 
option of 2 
additional 
sessions each 
year
Individual Health 
professionals:
Case managers
Medical staff
– Staff time: 
Questionnaire
Training 
materials: 
Questionnaire
Other 
components: 
Questionnaire
Year 1: 
$2,469
Year 2: 
$1,090
Year 3: 
$1,127
Year 4: 
$214
Year 5: 
$150
Year 6: 
$134
Year 7: 
$167
Year 8: 
$171
Year 9: 
$157
Year 10: 
$201
Total: 
$5,881
$102
Translational DPP
Kramer et al,
2009 (20); United States
42 Adults with prediabetes 
and/or metabolic syndrome
Community setting
Modified DPP (group lifestyle balance 
program)
1 y Core: 12 
group 
sessions
Maintenance: 
9 group 
sessions
Total: 21 
sessions
Group Health 
professionals:
Trained prevention 
professionals
– Staff time: 
Staff report
Training 
materials: NR
Other 
components: 
NR
$335 $16
Kramer et al, 2011 (21); 
United States
81 Adults with prediabetes 
and/or metabolic syndrome
Community setting
Modified DPP (group lifestyle balance 
program)
1 y Core: 12 
group 
sessions
Maintenance: 
9 group 
sessions
Total: 21 
sessions
Group Trained laypeople:
Diabetes educators
– Staff time: NR
Training 
materials: NR
Other 
components: 
NR
$357 $17
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Study, Year 
(Reference); Location Population Size, n Population Characteristics Intervention Setting/Intervention Format Duration
Intervention 
Intensity 
(Number of 
Sessions)
Method Type of Personnel
Cost Valuation for 
Identifying Clients 
(Recruitment; 
Screening)
Cost 
Valuation for 
Implementing 
the 
Intervention
Total 
Program 
Costs per 
Person
Cost per 
Person 
per 
Session
Krukowski et al, 2013 
(22); United States
116 Older adults (aged ≥60 y) 
who were obese (BMI ≥30 
kg/m2) and who had no 
significant memory 
problems
12-session translational DPP per reference 
20
1 y Core: 12 
weekly 
group 
sessions
Total: 12 
sessions
Group Trained laypeople:
Trained lay health 
educator
Recruitment: Staff 
compilation
Screening: -
Staff time: 
Staff 
compilation
Training 
materials: 
Staff 
compilation
Other 
components: 
Staff 
compilation
$191 $16
Vadheim et al, 
2010(23); United States
84 Adults at high risk for both 
diabetes and CVD
Community setting
Adapted DPP
10 mo Core: 1 6 
weekly 
group 
sessions
Maintenance: 
6 monthly 
group 
sessions
Total: 22 
sessions
Group Mixed health 
professional and 
trained laypeople:
Diabetes educator, 
nurse
– Staff time: NR
Training 
materials: NR
Other 
components: 
NR
$652 $30
Smith et al, 2010 (24); 
United States
NR BMI ≥25 kg/m2 and 
metabolic syndrome
2 urban and 2 rural medical practices in 
Pennsylvania
Modified DPP
To help patients with metabolic syndrome 
lose weight and improve at least 1 
metabolic syndrome component
3 mo 12 group 
sessions
Total: 12 
sessions
Group Mixed health 
professional and 
trained laypeople:
Trained health 
professional and 
lay health workers
Recruitment: -
Screening: NR
Staff time: NR
Training 
materials: NR
Other 
components: 
NR
$407 $34
Irvine et al, 2011 (25); 
United Kingdom
3,887 At-risk individuals with 
diabetes (aged 45–70 y)
Community setting
Delivered by Diabetes Prevention 
Facilitators
Promote a 7% weight loss within 6 mo 
using both diet and exercise
7 mo Core: 4 
group 
educational 
sessions in 3 
mo
Maintenance: 
4 monthly 
group 
sessions
Total: 8 
sessions
Group Mixed health 
professional and 
trained laypeople:
Diabetes 
prevention 
facilitators
Physicotherapist
Volunteers with 
diabetes
Recruitment: -
Screening: NR
Staff time: 
Questionnaire
Training 
materials: 
Questionnaire
Other 
components: 
Questionnaire
$443 $55
Ockene et al, 2012 (26); 
United States
312 Participants who were at 
high risk for type 2 diabetes
Community setting
LLDPP between 2004 and 2007
Healthy food choices, walking 4000 steps 
per day
1 y 3 individual 
and 13 group 
sessions
Total: 16 
sessions
Mixed 
group and 
individual
Trained laypeople:
Trained 
community health 
workers
– Staff time: NR
Training 
materials: NR
Other 
components: 
NR
$839 $53
Lawlor et al, 2013 (27); 
United States
301 Overweight or obese 
participants (BMI 25–39 
kg/m2) with elevated 
fasting blood glucose 
indicating prediabetes
Community setting
HELP PD trial
A DPP-based lifestyle weight-loss group
2 y Core: 26 
weekly 
group 
sessions and 
3 individual 
sessions in 6 
mo
Maintenance: 
18 monthly 
group 
sessions
Total: 47 
sessions
Mixed 
group and 
individual
Mixed health 
professional and 
trained laypeople:
Trained 
community health 
workers and 
dietician
Recruitment: -
Screening: NR
Staff time: 
Questionnaire
Training 
materials: 
Questionnaire
Other 
components: 
Questionnaire
Year 
1:$613
Year 2: 
$305
Total: $918
$20
Translational non-DPP
Feldman et al, 2013 
(28); Sweden
142 KMSP in primary care, 
diagnosed with metabolic 
syndrome
Primary care
Promote healthy lifestyles, in particular 
changes in dietary and physical activity 
habits
1 y Core: 26 
group 
lifestyle 
counseling 
and support 
sessions 
twice a week 
for 3 mo
Maintenance: 
18 biweekly 
group 
counseling 
and support 
sessions for 
9 mo
Total: 44 
sessions
Group Health 
professional:
Practice nurses
Health coordinator
Recruitment: 
Program 
documentation
Screening: -
Staff time: 
Program 
documentation
Training 
materials: 
Program 
documentation
Other 
components: 
Program 
documentation
$427* $10*
Sagarra et al, 2014 (29); 
Spain
552 Aged 45–75 y at risk for 
diabetes with IGT and/or 
IFG
Primary care setting
DE-PLAN project
6-h structured lifestyle intervention (diet 
and physical activity) similar to Finnish 
DPS using specific teaching techniques
Individual or group format
4.2 y Year 1: 4 
sessions (6 
h)
Years 2–4: 
Continuous 
intervention 
through 
telephone 
calls, text 
message, 
letters, and 
interviews, 
scheduled for 
every 6–8 wk
Group or 
individual 
(2 
groups)
Health 
professional:
Physicians, nurses, 
and dieticians
Recruitment: Forms
Screening: Forms
Staff time: 
Forms
Training 
materials: 
Forms
Other 
components: 
Forms
$1,133 for 
the whole 
intensive 
intervention 
group
$1,077 for 
the group 
format
$1,242 for 
the 
individual 
format
$4 for the 
group 
format*
$43 for 
individual 
format*
Jacobs-van der 
Bruggen, 2007 (30); 
Netherlands
NR Adults with moderate risks 
for diabetes, obese adults 
aged 30–70 y
Community setting
Nutrition and exercise for adults with 
moderate risks for diabetes
3 y Year 1: 4 
individual 
and 1 group 
session; 1 
individual 
advice by a 
researcher; 
52 weekly 
fitness 
programs
Years 2–3: 3 
individual 
and 1 group 
session; 52 
biweekly 
fitness 
programs
Total: 114 
sessions
Nutrition: 9 
sessions
Fitness: 105 
sessions
Mixed 
group and 
individual
Health 
professionals:
Dietitian, not clear 
who delivered the 
fitness program
– Staff time: 
Questionnaire
Training 
materials: 
Questionnaire
Other 
components: 
Questionnaire
$1,416 Regular 
session: 
$64
Fitness: 
$8
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BMI = body mass index; CVD = cardiovascular disease; DE-PLAN = Diabetes in Europe: Prevention Using Lifestyle, 
Physical Activity, and Nutritional Intervention; DPP = Diabetes Prevention Program; DPPOS = Diabetes Prevention 
Program Outcomes Study; DPS = Diabetes Prevention Study; HELP PD = Healthy Living Partnerships to Prevent Diabetes; 
IFG = impaired fasting glucose; IGT = impaired glucose tolerance; KMSP = Kalmar Metabolic Syndrome Program; 
LLDPP = Lawrence Latino Diabetes Prevention Project; NR = not reported.
*Only included cost to deliver lifestyle intervention.
Appendix Table 3
Summary Evidence Table of Included Studies Providing Cost-Effectiveness of Combined 
Diet and Physical Activity Promotion Programs to Reduce Type 2 Diabetes Among Persons 
at Increased Risk
Study, Year (Reference); 
Country
Population Characteristics Duration of Intervention/Follow-up Cost Data Source Benefit Data Source Effectiveness Outcome Model QALY/DALY/LYG ICER Health System ICER Society
Within-trial analysis (n=4)
DPP Research Group, 2003 
(31); United States*
IGT 3 y/3 y Real DPP cost 
data
Survey, CMS fee 
schedule
Reduce incidence by 
58%
Within trial 0.072 additional QALY Individual: $50,694/QALY
Group: $14,476/QALY
Individual: $83,130/QALY
Group: $46,820/QALY
DPP Research Group, 2012 
(19); United States*
Participants with IGT and 
fasting hyperglycemia, ≥25 
y, BMI ≥24 kg/m2, 68% 
women, 45% minority
10 y/10 y Real DPP cost 
data
Survey DPPOS trial
0.12 additional QALY
Within trial 0.12 additional QALY Individual $15,846/QALY
Group: $1,819/QALY
Individual $24,373/QALY
Group: $10,351/QALY
Irvine et al, 2011 (25); 
United Kingdom
At-risk individuals with 
diabetes (aged 45–70 y)
7 mo/7 mo Real cost data Survey, NHS reference 
cost, drug formulary
0.012 additional QALY Within trial 0.012 additional QALY $40,347/QALY †
Sagarra et al, 2014 (29); 
Spain
Aged 45–75 y, at risk for 
diabetes with IGT and/or 
IFG
4.2 y/4.2 y Real cost data Forms Reduce incidence by 
36.5%
0.012 additional QALY
Within trial 0.012 additional QALY $5,359/QALY †
Modeling the trial or 
extension of trials (n = 16)
Segal et al, 1998 (32); 
Australia
Seriously obese
Seriously obese with IGT or 
NGT
2–3 y/25 y Based on literature Survey, insurance scheme Reducing incidence 
from 70% to 30%
Markov model 1 additional LYG $4,561/LYG †
Caro et al, 2004 (33); 
Canada
Overweight or obese with 
IGT
5 y/10 y Based on Finnish 
DPS
Literature, fee schedule, 
formularies
Based on DPP, Finnish 
DPS
At 5th year, incidence 
−58%
At 10th year, incidence 
−22%
Markov model 0.31 additional LYG $806/LYG †
Palmer et al, 2004 (34); 
Australia, France, Germany, 
Switzerland, United 
Kingdom
IGT 3 y/lifetime DPP apply to fee 
schedule
Claims Based on DPP, 
assuming the effect 
would not persist 
beyond the 3rd year
Markov model 0.08 (Australia)
0.07 (France)
0.07 (Germany)
0.06 (Switzerland)
0.16 (United Kingdom)
−$8.176/LYG (Australia)
−$11,682/LYG (France)
−$15.018/LYG (Germany)
−$19,029/LYG 
(Switzerland)
$8.565/LYG (United 
Kingdom)
Mean: −$9.073/LYG
†
Eddy et al, 2005 (35); 
United States*
IGT Until diabetes onset/30 y Year 1 to 3: DPP 
cost
Year 4 and 
beyond: DPP year 
3 cost
Accounting data Effect of DPP persists 
as long as receiving the 
intervention
At end of 30 y, 
incidence −15%
Archimedes Diabetes Model 0.159 additional QALY Individual $94,752/QALY
Group: $18,409/QALY
Individual: $221,549/
QALY (HMO perspective)
Group: $41,879/QALY 
(HMO perspective)
–
Herman et al, 2005 (36); 
United States
IGT Until diabetes onset/lifetime Year 1 to 3: DPP 
cost
Year 4 and 
beyond: DPP year 
3 cost
Claims The effect of DPP 
persists as long as 
receiving the 
intervention
At the end of lifetime, 
incidence −24%
Markov model 0.57 additional QALY Individual: $1,805/QALY
Group: −$10,450/QALY
Individual: $13,574/QALY
Ackerman et al, 2006 (37); 
United States
Overweight or obese 50-
year-old adults with IGT
Until diabetes onset/lifetime Year 1 to 3: DPP 
cost
Year 4 and 
beyond: DPP year 
3 cost
Claims Based on DPP
The DPP effect will 
continue as long as 
receiving intervention
Markov model Age 50 y: 0.59 additional 
QALY
Age 65 y: 0.27 additional 
QALY
Age 50 y: $2,070/QALY
Age 65 y: $2,536/QALY †
Hoerger et al, 2007 (38); 
United States*
Aged 45–74 y, overweight 
and obese (BMI ≥25 
kg/m2)
Groups
Until diabetes onset/lifetime Year 1 to 3: DPP 
cost
Year 4 and 
beyond: DPP year 
3 cost
Claims The effect of DPP 
persists as long as 
receiving the 
intervention
Markov model 0.040 additional QALY Individual: $14,154/QALY
Group: $396/QALY
Individual: $28,849/QALY
Jacobs-van der Bruggen et 
al, 2007 (30); Netherlands
Adults with moderate risks 
for diabetes, obese adults 
aged 30–70 y
3 y/lifetime 2 published Dutch 
trials
Literature BMI: −0.3 to −1.5 
kg/m2
Physical activity: 50%
−75% more from 
inactive to moderately 
active, 20% more from 
moderately to active
Markov model 1.17 additional QALY $8,735/QALY †
Lindaren et al, 2007 (39); 
Sweden
IGT
Age 60 y
BMI >25 kg/m2, FPG 
>6.1
6 y/lifetime Finnish DPS Literature Based on Finnish DPS; 
no lasting effect if the 
intervention stops
Markov model 0.2 additional QALY $14,852/LYG
$13,367/QALY
$6,756/LYG
$6,080/QALY
Gillies et al, 2008 (40); 
United Kingdom
NR Until diabetes onset/50 y A systematic 
review of weight 
loss programs
Literature, such as 
UKPDS
Hazard ratio, −0.649 
from review
Markov model 0.05 additional LYG
0.09 additional QALY
$25,083/LYG
$14,352/QALY †
Bertram et al, 2010(41); 
Australia
Age >55 y, or age >45 y 
plus high BMI, family 
history of type 2 diabetes 
mellitus or hypertension; 
people from “high-risk” 
groups
Average trial period/lifetime A systematic 
review and meta-
analysis of 
lifestyle 
interventions
Benefit schedule Based on meta-analysis
Relative risk: 0.49
Assuming 10% decay 
of effect after the 
intervention
Microsimulation model 0.05 additional DALY 
averted
$21,195/DALY †
Smith et al, 2010 (24); 
United States BMI ≥25 kg/m2 and 
metabolic syndrome
3 mo/3 y A community-
based DPP in 
Pennsylvania, 
United States
Literature (DPP, UKPDS, 
Framingham Heart 
Study)
By 1 y, metabolic risk: 
−16.2%
By 3 y, risk:−19%
Markov model 0.01 QALY $5,494/QALY †
Neumann et al, 2011 (42); 
Germany
FINDRISC between 11–20, 
or FINDRISC ≥21 and 
without diagnosis of 
diabetes
5 y/lifetime SDPP CODE-2 study 
calculation of average 
annual direct health care 
costs of persons with 
NGT, IGT, and type 2 
diabetes
Based on literature, 
such as PREDIAS and 
SDPP in Germany
Assuming the 
effectiveness of the 
intervention lasts only 
for 1 y after the 
Markov model 0.02–0.03 QALY 
depending on sex and age † Age 30 y: −$41,772/QALY for men, −$52,136/
QALY for women
Age 50 y: −$25,079/
QALY for men, −$35,217/
QALY for women
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Study, Year (Reference); 
Country
Population Characteristics Duration of Intervention/Follow-up Cost Data Source Benefit Data Source Effectiveness Outcome Model QALY/DALY/LYG ICER Health System ICER Society
intervention (disappears 
at 7th year)
Age 70 y: $39,666/QALY 
for men, $32,259/QALY 
for women
Palmer et al, 2012 (43); 
Australia
NR 10 y/lifetime DPPOS, using 
medical benefits 
schedule in 
Australia
Survey, unit cost data in 
Australia
Based on DPPOS trial 
0.12 additional QALY
Semi-Markov simulation 0.3 LYG
0.12 QALY
−$234/LYG
−$411/QALY †
Feldman et al, 2013 (28); 
Sweden
NR 1 y/lifetime Based on a 
lifestyle trial in 
Sweden
Swedish previously 
published studies
Based on the KMSP in 
Sweden
Assuming effect 
continued at year 2 then 
gradually decreased, 
reaching the level at the 
start in year 5 and 
beyond (e.g., −0.4 to 
−1.1) in BMI in 
different risk groups
+2 to −7 in waist 
circumference
+0.2 to −0.6 in fasting 
glucose
Markov model 0.05–0.14 additional QALY $4,104/QALY for men 
with high risk
$23,327/QALY for women 
with high risk
Cost-saving for men with 
high risk
$22,647/QALY for women 
with high risk
Png and Yoong, 2014 (44); 
Singapore
IGT 3 y/3 y DPP, applying unit 
cost obtained from 
the Singapore 
National 
University 
Hospital cost 
repository
Singapore 
Household 
Expenditure 
Survey
Singapore National 
University Hospital cost 
repository
Based on 3-y DPP trial, 
not explicitly reporting 
the risk reduction
Markov model 0.05 QALY $17,614/QALY $37,580/QALY
Modeling nationwide 
diabetes prevention 
programs (n = 2)
Colagiuri and Walker, 2008 
(45); Australia
Australians aged 45–74 y 10 y/1 0 y An unspecified 
“lifestyle 
program” at 
Australia, $500 
per person per 
year
Literature, such as 
UKPDS
Diabetes incidence in 
IGT: −60%
In IFG: −30%
Markov model 36,009 additional DALY 
averted in the whole nation
$50,707/DALY †
Zhuo et al, 2012 (46); 
United States
18–64 y and 65–84 y U.S. 
population
Until diabetes onset/25 y Year 1: Based on 
YMCA-DPP
Year beyond: 
Based on DPPOS 
maintenance 
period
Claims Year 1: Diabetes 
incidence: −40% to 
−50%
Year 2: Diabetes 
incidence: −40% to 
−50%
Year 3 and beyond: −10 
to −15%
Markov model 0.04 additional LYG
0.03 additional QALY
16–64 y: −$8,378/QALY
65–84 y: −$5,760/QALY †
BMI = body mass index; CMS = Centers for Medicare & Medicaid Services; CODE-2 = Cost of Diabetes in Europe–Type 
2; DALY = disability-adjusted life-year; DPP = Diabetes Prevention Program; DPPOS = Diabetes Prevention Program 
Outcomes Study; DPS = Diabetes Prevention Study; FINDRISC = Finnish Type 2 Diabetes Risk Score; FPG = fasting 
plasma glucose; ICER = incremental cost-effectiveness ratio; IFG = impaired fasting glucose; IGT = impaired glucose 
tolerance; KMSP = Kalmar Metabolic Syndrome Program; LYG = life-year gained; NGT = normal glucose tolerance; NHS 
= National Health Service; NR = not reported; PREDIAS = Prevention of Diabetes Self-management Program; QALY = 
quality-adjusted life-year; SDPP = Saxon Diabetes Prevention Programme; UKPDS = United Kingdom Prospective 
Diabetes Study; YMCA = Young Men’s Christian Association.
*Study reported from “societal perspective”; however, it was actually from “health system perspective” because only costs 
to the health system were included.
†Study did not include or report the cost or cost-effectiveness for the category.
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Figure 1. 
Summary of evidence search and selection.
*Studies had abstracts only, were irrelevant, or did not meet inclusion criteria.
†Did not meet inclusion criteria (for example, included persons with diabetes or had 
physical activity or diet component but not both). Two studies were conducted in low- or 
middle-income countries, and 1 did not follow a rigorous cost–benefit analysis.
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Figure 2. 
Scatterplot of ICERs from 16 cost-effectiveness or cost–utility analyses that reported cost 
per QALY saved from the health system perspective.
DPP = Diabetes Prevention Program; ICER = incremental cost-effectiveness ratio; IQI = 
interquartile interval; QALY = quality-adjusted life-year.
*$13 761 per QALY saved (IQI, $3067 to $21 899).
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Table 1
Comparison of Program Costs, by Program Delivery Setting, Method, and Personnel
Group Studies, n Median Total Cost per Participant (IQI or 
Range), 2013 U.S. $*
Median Cost per Participant per Session 
(IQI or Range), 2013 U.S. $*
Setting
 DPP/DPPOS† 1 5881 102
 Translational DPP 8   424 (IQI, 340–793) 25 (IQI, 16–48)
 Translational non-DPP‡ 3 1160 (range, 427–1416) 27 (range, 4–64)
Delivery method§
 Individual-based 2 5881 and 1242 102 and 44
 Group-based 8   417 (IQI, 341–600) 17 (IQI, 12–33)
 Mixed 3 839, 918, and 1416 8, 20, and 53
Personnel
 Health professionals‖ 4 1077 (IQI, 381–1329) 16 (IQI, 7–54)
 Trained laypersons 3   191, 357, and 839 16, 17, and 53
 Mixed 4   548 (range, 407–918) 31 (IQI, 20–55)
DPP = Diabetes Prevention Program; DPPOS = Diabetes Prevention Program Outcomes Study; IQI = interquartile interval.
*
Range is provided if there were 4 data points; values from individual studies are provided if there were ≤3 data points.
†Cost per participant was calculated for the DPP/DPPOS. Cost per participant per session was calculated for DPP core sessions.
‡4 data points; 1 study reported data points from 2 groups.
§1 study reported data points from individual- and group-based groups.
‖
Includes only translational studies, not the DPP trial; 5 data points; 1 study reported data points from 2 groups.
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Table 2
Comparison of Costs per QALY Saved, by Dimension
Group Studies, n Median ICER* (IQI or Range), $/QALY†
Study perspective‡
 Societal perspective includes only indirect cost
  Health system   2 13 367 and 23 327
  Societal   2 6080 and 22 647
 Societal perspective includes only direct nonmedical cost
  Health system   4 15 000 (range, 1805 to 50 694)
  Societal   4 26 611 (range, 13 574 to 83 310)
 Societal perspective includes direct nonmedical and indirect costs
  Health system   1 17 614
  Societal   1 37 580
Delivery method‡
 Individual-based   5 15 846 (IQI, 7980 to 72 723)
 Group-based   5 1819 (IQI, −5027 to 16 443)
Setting
 United States   8 9824 (IQI, 1930 to 41 982)
 Other   8 13 860 (IQI, 6203 to 21 899)
Method
 Within-trial   4 28 097 (range, 5359 to 50 694)
 Modeling extension of trials 11 13 367 (IQI, 2303 to 17 614)
 Modeling on nationwide, community-based DPP   1 −7069
Time horizon
 Short-term (<10 y)   5 17 614 (IQI, 5427 to 45 521)
 Long-term (≥10 y) 11 13 367 (IQI, 1805 to 15 846)
DPP = Diabetes Prevention Program; ICER = incremental cost-effectiveness ratio; IQI = interquartile interval; QALY = quality-adjusted life-year.
*
From health system perspective unless otherwise indicated.
†
Range is provided if there were 4 data points; values from individual studies are provided if there were ≤3 data points. Costs are in 2013 U.S. 
dollars.
‡
Data are from the same studies (i.e., the studies reported ICERs from both societal and health system perspectives or from both individual and 
group delivery methods).
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